JP
Therapeutic Areas
Evolus Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Jeuveau® (prabotulinumtoxinA-xvfs) | Temporary improvement of moderate to severe glabellar lines (frown lines) | Approved |
| Jeuveau® | Temporary improvement of lateral canthal lines (crow's feet) | Phase 3 |
| Daxxify® (daxibotulinumtoxinA-lanm) | Aesthetic indications (via partnership) | Approved |
Leadership Team at Evolus
DM
David Moatazedi
President, Chief Executive Officer, and Director
SB
Sandra Beaver
Chief Financial Officer
RA
Rui Avelar, M.D.
Chief Medical Officer and Head of R&D
LS
Lauren Silvernail
Chief Commercial Officer
MJ
Michael J. Brown
General Counsel and Corporate Secretary
BB
Brittany Bradrick
Chief Corporate Affairs Officer
CS
Carrie Strom
Board Member
VM
Vikram Malik
Board Member
GM
G. Michael Finley
Board Member
BR
Bryan Reasons
Board Member